Clinical trials: Breakthrough Cancer Pain
Metastatic Disease
MAnagement of METastatic Disease in Campania (MAMETIC)
The MAMETIC Trial represents the first regional epidemiological study that aims to evaluate patients living in Campania with metastatic cancer, with the intent to detect different prevalence of tumors in the metastatic phase and…
- Trial name
- MAMETIC (NCT04595032)
- Testing
- 3DCRT, IMRT, VMAT, SBRT
- Where
- Italy
- Volunteers
- 3,234 people
- Sponsor
- National Cancer Institute, Naples
Neoplasms, Pain
The Pain Pen for Breakthrough Cancer Pain
The purpose of this study is to see whether injection of hydromorphone through a subcutaneous injection device is more effective in treating breakthrough cancer pain than oral morphine.
- Trial name
- NCT00125801
- Testing
- Subcutaneous hydromorphone delivered by pain pen
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Erasmus Medical Center
Pain
An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients.
Lazanda is a prescription nasal spray medicine that contains the medicine fentanyl. It is used to manage breakthrough pain in adults with cancer who are already routinely taking other opioid pain medicines around-the-clock for…
- Trial name
- FCNS (NCT01839552)
- Testing
- Fentanyl Citrate Nasal Spray (FCNS)
- Where
- United States
- Sponsor
- University of Louisville
Breakthrough Pain
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
The primary objective of the study is to determine whether a test titration regimen of ACTIQ treatment will reduce the number of inadequately managed episodes of breakthrough pain for an individual patient by attaining a…
- Trial name
- NCT00236145
- Testing
- ACTIQ (Oral transmucosal fentanyl citrate)
- Sponsor
- Cephalon
Breakthrough Pain, Mucositis
Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal Mucositis
An open-label, non-randomized study to assess the titration, safety and efficacy of intranasal fentanyl pectin nasal spray for the treatment of secondary breakthrough pain secondary to radiation-induced mucositis in patients with…
- Conditions
- Breakthrough Pain, Mucositis, Radiotherapy, Chemotherapy
- Trial name
- CP073 (NCT02050503)
- Where
- Spain
- Volunteers
- 33 people
- Sponsor
- Grupo de Investigación Clínica en Oncología Radioterapia
Breakthrough Pain, Palliative Medicine
Paediatric Breakthrough Pain Assessment
Many children and young people with life-limiting and life-threatening illnesses get sudden bursts of pain called breakthrough pain. At the moment, there aren't any good ways to measure this pain in children and young people.
- Conditions
- Breakthrough Pain, Palliative Medicine, Oncology Pain, Pediatric ALL
- Trial name
- BEACON (NCT06790719)
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- University of Southampton
Tumor, Cancer Pain
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
The BTP (Breakthrough pain)was defined as "a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled…
- Conditions
- Tumor, Cancer Pain, Breakthrough Cancer Pain, Neuropathic Pain
- Trial name
- RER (NCT01946555)
- Testing
- Morphine, Fentanyl, Methadone
- Where
- 11 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Cancers, Pain
Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Cancer patients taking regular medication for their pain often still have episodes of severe pain that 'break through' despite their background pain treatment.
- Trial name
- NCT00589823
- Testing
- Fentanyl citrate, Immediate release morphine sulphate
- Where
- United Kingdom
- Volunteers
- 135 people
- Sponsor
- Archimedes Development Ltd
Cancer, Pain
An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer
The purpose of this study is to evaluate the clinical efficacy of hydromorphone hydrochloride (HCl) Oral Osmotic System (OROS) by assessing the extent of reduction of medication frequency for the management of breakthrough pain…
- Trial name
- NCT01006356
- Testing
- Hydromorphone HCl OROS
- Volunteers
- 141 people
- Sponsor
- Janssen Korea, Ltd., Korea
Pain, Cancer
Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.
- Trial name
- NCT00105287
- Testing
- OraVescent fentanyl (OVF)
- Where
- 26 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cephalon
Breakthrough Cancer Pain
Patient Satisfaction and Quality of Life Impact - PecFent®
National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of…
- Trial name
- Qualipec (NCT01693328)
- Testing
- PecFent® (fentanyl) nasal spray
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Archimedes Development Ltd
Breakthrough Cancer Pain
Patient Satisfaction and Quality of Life Impact - PecFent®
National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of…
- Trial name
- Qualipec (NCT01698645)
- Testing
- PecFent® (fentanyl) nasal spray
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Archimedes Development Ltd
Cancer, Pain
Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients
The purpose of this Phase II study is to determine the feasibility of the dose titration and assessment protocol in the outpatient population before conducting an appropriately powered phase III study.
- Trial name
- NCT00351715
- Testing
- Sublingual Methadone
- Where
- 2 sites in Canada
- Volunteers
- 5 people
- Sponsor
- AHS Cancer Control Alberta
Pain, Cancer
Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy
The purpose of this study is to evaluate the safety of BEMA fentanyl at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy.
- Trial name
- NCT00293020
- Testing
- BEMA Fentanyl
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- BioDelivery Sciences International